Decision making under ambiguity and risk in adolescent-onset schizophrenia

BMC Psychiatry

Table 1 Demographic and neuropsychological performances in patients with AOS and healthy controls (M ± SD)

Items	Patients with AOS	Healthy controls	*T/x*²	P value
Number of participants	71	53
Gender (male/female)	40/31	23/30	2.034	0.154
Age (years)	16.11 ± 1.38	15.80 ± 0.87	1.649	0.102
Educational year	9.87 ± 1.47	10.47 ± 0.82	−1.688	0.094
MoCA	27.67 ± 1.99	28.6 ± 1.49	−2.495	0.015*
Stroop Color	17.02 ± 5.39	12.25 ± 2,78	6700	< 0.001***
Stroop Word	20.30 ± 7.02	14.68 ± 3.90	5940	< 0.001***
Stroop Color&Word	33.16 ± 13.46	26.34 ± 9.05	3.546	0.001***
DS-Forward	7.96 ± 0.25	7.96 ± 0.18	−0.069	0.945
DS-Backward	5.45 ± 1.15	6.31 ± 0.84	−4.677	< 0.001***
PANSS-P	13.81 ± 6.27
PANSS-N	13.44 ± 6.45
PANSS-T	54.81 ± 14.77
CPZeq of total antipsychotic drugs (mg/day)	441.55 ± 115.76

Note: MoCA Montreal Cognitive Assessment; Stroop Stroop Color Word Tasks; PANSS Positive and Negative Syndrome Scale. PANSS - P PANSS Positive Subscale Score; PANSS - N PANSS Negative Subscale Score; PANSS - T PANSS Total Score; DS The Digital Span Test, CPZ - eq Chlorpromazine - equivalent.* p < 0.05, *** p < 0.001

ISSN: 1471-244X